REGENXBIO has successfully completed patient recruitment for the second group in the Phase I/II AFFINITY DUCHENNE® clinical trial, which is examining the safety and effectiveness of RGX-202.

REGENXBIO Inc. (Nasdaq: RGNX) revealed that the Phase I/II/III CAMPSIITE® clinical trial for RGX-121, a treatment for Mucopolysaccharidosis Type II (MPS II).

Genenta Science, a clinical-stage biotech firm specializing in immuno-oncology, has made significant progress in its Phase 1/2 clinical trial for Temferon™.

Belhaven Biopharma announced promising results from its Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device for treating anaphylaxis due to severe allergic reactions.

Hemogenyx Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) to commence Phase I clinical trials for its innovative HEMO-CAR-T treatment for acute myeloid leukemia (AML).

HMB-001, a novel bispecific antibody developed by Hemab Therapeutics, has shown promising results in Phase 1 clinical trials for treating Glanzmann Thrombasthenia.

Anixa Biosciences has initiated treatment for a fourth participant in its Phase 1 clinical trial for a new CAR-T cell therapy aimed at ovarian cancer.

Nuvalent has commenced the Phase 2 stage of the ALKOVE-1 clinical trial for NVL-655, a novel ALK-selective tyrosine kinase inhibitor (TKI).

Protagenic Therapeutics, Inc. has made progress in its clinical trial for a new brain peptide compound called PT00114.

The Phase 1b/2a AMARONE clinical trial's 12-week results indicate that Restoret, developed by Eyebiotech Limited, is well-tolerated in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Medicenna Therapeutics has initiated a Phase 1/2 clinical trial, known as the ABILITY-1 study, to assess the safety and efficacy of MDNA11, a modified version of interleukin-2 (IL-2).

A recent clinical study by Kiromic BioPharma, Inc. has shown positive results in the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC) with their drug candidate, Deltacel™.